WEST PHARMACEUTICAL SERVICES INC (WST) Stock
WST has an Alpha Score of 55 out of 100 (moderate), computed on Nov 1, 2026 from 3 of 4 sub-scores. 8 members of Congress disclosed 14 trades in WST since 2015: 7 purchases and 7 sales, most recently Lisa McClain (sale, Jul 22, 2025). 7 of the hedge funds AlphaScala tracks reported WST in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $126.64M. Company insiders reported 0 open-market buys and 6 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 52.3 and its net margin 17.0% (key statistics as of Nov 2, 2026).
What is WST's Alpha Score?
How it works →Alpha Score of 55 reflects moderate overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 1, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded WEST PHARMACEUTICAL SERVICES INC (WST)?
Most recent: Lisa McClain (sale, Jul 22, 2025); records start Feb 13, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-07-22 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-02-25 | purchase | $1k – $15k |
| Jared Moskowitz D-FL · House | 2025-02-13 | sale | $1k – $15k |
| Jared Moskowitz D-FL · House | 2024-11-08 | sale | $1k – $15k |
| Jared Moskowitz D-FL · House | 2023-12-28 | purchase | $1k – $15k |
| Jared Moskowitz D-FL · House | 2023-07-14 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all WST political trades →Which hedge funds own WST?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 353K | $126.64M | +9% |
| Point72 Steve Cohen | 283K | $101.74M | +78% |
| Marshall Wace | 84K | $30.00M | +5213% |
| Renaissance Technologies Jim Simons (founder) | 31K | $11.09M | -85% |
| Millennium Management Israel Englander | 21K | $7.64M | +55% |
| D.E. Shaw David Shaw | 13K | $4.63M | -8% |
| Bridgewater Associates Ray Dalio | 10K | $3.74M | -55% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are WEST PHARMACEUTICAL SERVICES INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 15, 26 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2.5K | $921K |
| Sep 14, 26 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2.5K | $888K |
| Sep 11, 26 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2.5K | $863K |
| Sep 8, 26 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2.8K | $960K |
| Sep 8, 26 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2.8K | $960K |
| Sep 8, 26 | Favorite Annette F | Sr. VP & Chief HR Officer | SELL | 2.5K | $852K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are WST's key statistics?
Key statistics as of Nov 2, 2026
How does WST's valuation compare with the Healthcare sector?
| Metric | WST | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 52.3 | 28.8 | 111 |
| Net margin | 16.98% | 4.31% | 164 |
| Return on equity | 18.51% | 5.47% | 185 |
| Dividend yield (payers) | 0.33% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
WST price chart
Powered by TradingViewWhat does WEST PHARMACEUTICAL SERVICES INC do?
West Pharmaceutical Services, Inc. is a global leader in designing and manufacturing drug packaging and delivery solutions for pharmaceutical, biotechnology, and medical device industries. The company specializes in elastomeric and polymer components that maintain the integrity and safety of injectable medicines, including vial stoppers, syringe plungers, cartridge-based delivery systems, and complete safety-engineered administration devices. Its product portfolio encompasses containment and delivery platforms supporting traditional small-molecule injectables and advanced biologics, along with prefillable syringe systems, custom-engineered polymer components, and integrated safety systems to reduce needlestick injuries and improve patient compliance. West Pharmaceutical Services, Inc. also offers design, testing, and regulatory support to assist customers in accelerating development timelines while meeting global quality standards. Operating through Proprietary Products and Contract-Manufactured Products segments, it manufactures pharmaceuticals, biologics, vaccines, and consumer healthcare products. Founded in 1923 and headquartered in Exton, Pennsylvania, the company maintains manufacturing facilities, R&D centers, and technical service laboratories across North America, Europe, and Asia-Pacific, fostering collaboration with leading drug firms worldwide.